Description
Like most cystatin genes, the human CST6 gene is organized into three exons separated by two introns. Exon-1 is 294-bp long, contains the 5'-untranslated region (5'-UTR) and the starting ATG codon of the coding sequence. Exon-2 is 126-bp long. Exon-3 is 188-bp long, contains a TGA stop codon, the 3'-UTR as well as a typical AATAAA polyadenylation signal followed by 20 bp. Intron-1 and intron-2 are 541-and 365-bp in length, respectively.
Transcription
The human CST6 gene is transcribed into a single mRNA species of about 607 nucleotides (nt). There are no alternate transcript species. The transcript is composed of a 5'-UTR of 53 nt, a coding sequence of 447 nt, and a 3'-UTR of 107 nt. A palyndromic structure located some 360 nt downstream of the AUG initiation codon (or 26 codons upstream of the TGA stop codon) seems to be responsible for some sequence variation in that region. Indeed, several expressed sequence tags (ESTs) differ primarily if not solely in that region of the mRNA sequence. Transcription from the CST6 gene promoter seems to be both constitutive and regulated. Numerous potential SP1 binding sites (TESS/TransFac database v4.0) in the CST6 promoter may account for a low to moderate basal promoter activity in many tissues. High expression occurs only in a few tissues such as the skin, placenta, ovary, pancreas and the lungs. A quite widespread expression of CST6 is also supported by data extracted from gene expression libraries (GEO, GeneNote, GNF Symatlas, CGAP, EST, SAGE, and UniGene eNortherns). However, there are some conflicting data in the literature suggesting that the CST6 mRNA is expressed in a tissue-specific manner mainly if not exclusively in the skin. Expression from the human CST6 gene is epigenetically silenced in several tumor types (see below). The 5'-end of the CST6 gene including exon-1 has an unusually high (≥ 70%) content in G and C nucleotides. As a matter of fact, a typical CpG island spans across the transcription start site (bp +1) from bp -186 to bp +320 and encompasses all of exon-1. Not surprisingly, treatment of tumor cells by histone deacetylase or DNA methyltransferase inhibitors results in 're-expression' of CST6 at levels similar to those seen in the normal or benign counterparts. The unusual GC content (~ 80%) of the 5'-UTR of the mRNA suggests that CST6 expression might also be regulated at the translational level by eIF-4E.
Pseudogene
No pseudogenes have been identified.
Protein

Note
The CST6 gene product, Cst6, is a typical secretory protein. It is synthesized as a preprotein with a patent N-terminal signal sequence. The protein is translocated into the rough endoplasmic reticulum where about 30-50% of the nascent Cst6 polypeptides are Nglycosylated. Upon SDS-PAGE, Cst6 harvested from most cell secretions migrates as two major forms, a 14-kDa unglycosylated and a 17-to 18-kDa glycosylated form.
Description
The three-dimensional organization of Cst6 (assuming it is similar to that of chicken egg white cystatin shown in figure 4) is that of a compact five-pleated beta-sheet that partially wraps around a central alpha-helix. It is not clear what role glycosylation of residue N 137 fulfills. Perhaps, N-glycosylation promotes binding of the protein to cells and entry into the endosomal/lysosomal system where Cst6 can interact with target proteases.
Expression
Cst6 is a cell-secreted protein. In vitro, the majority (> 95%) of the protein accumulates in the media conditioned by the cells. In cells that overexpress Cst6, prominent labeling of the Golgi apparatus can be seen using indirect immunofluorescence cytochemistry.
Localisation
In the human skin, where localisation of Cst6 has been most carefully explored, the protein is detected in the stratum granulosum of the epidermis, in the outer root sheet of hair follicles, in the secretory coil epithelium of sweat glands, and in the inner, mature cells of sebaceous glands. Figure 4 : Typical crystal structure of a secretory cystatin. The coordinates for the crystal structure of chicken egg white cystatin (1CEW) were obtained from the PDB database. A 3D-model of the cystatin was then generated using SwissPDB-Viewer. The N-and C-termini of the protein are marked by 'N' and 'C', respectively. The two conserved disulfide bonds are highlighted in yellow. The amino acids that are part of the two distinct binding sites for lysosomal cysteine proteases are labeled by purple and yellow boxes as described in the legend to figure 3. N64 and W135 are particularly important in this regard and are highlighted in blue. The amino acid numbering refers to that of the Cst6 preprotein, i.e., the protein with a 28-amino acid signal peptide (not present).
Some cystatins such as Cst6 are double-headed inhibitors and have a second inhibitory site, i.e., N 64 in figures 3 and 4 above. Via this alternate inhibitory site, Cst6 is capable of binding and inhibiting legumain-type cysteine proteases such as AEP/mammalian legumain. Cystatins do not inhibit caspases and calpains seem to be regulated in a different manner. Little is known about the inhibitory potential of cystatins towards other types of intracellular cysteine proteases.
Epithelial barrier function:
One important function of Cst6 seems to be in the terminal differentiation of stratified squamous epithelial cells and in the formation of cornified envelops. Indeed, ichq mice with a null mutation in the cst6 gene develop neonatal abnormalities in skin cornification and desquamation that resemble Harlequin ichthyoses in humans. However, no alterations in the CST6 gene were found in the DNA of patients with Harlequin ichthyosis.
In mice, the lack of Cst6 function leads to severe dehydration and neonatal lethality. Before serving as a substrate to transglutaminases and being deposited into cornified cell envelops, Cst6 is believed to be important in fine-tuning the enzymatic activities of endosomal/lysosomal cysteine proteases such as cathepsin L, cathepsin L2/V and AEP/mammalian legumain. Deregulated activity of these proteases could lead to abnormal activation of transglutaminases and disorders in cornification. 
Homology
Germinal
No germ-line mutations have been detected.
Implicated in
Cancer progression
Loss of heterozygosity (LOH) affecting the locus 11q13 is quite common in cancers. This locus indeed harbors several tumor or metastasis suppressor genes such as BAD, MEN1, BRMS1, RASGRP2, GSTP1 and CST6. In a study using differential RNA display it was initially established that human breast cancer cell lines exhibited lack or reduced CST6 expression when compared to immortal or normal counterparts. CST6 was coined a novel candidate tumor suppressor gene for breast cancer on October 1st, 2004. Since then, several groups have reported on the lack or diminished expression of CST6 in various cancer types (listed below). However, some groups also observed overexpression of CST6 in select cancer types (listed below). One of the challenges in current research on CST6 is to define the proteases targeted by CST6 and their precise role in the progression of the disease. 
Cervical cancer
Note
One study recently reported on the lack of CST6 expression in 9/11 (82%) primary squamous cell carcinomas of the cervix, but expression of the gene in 5/5 (100%) normal cervical tissues as well as in normal lung, thyroid, kidney, brain, ovary, uterus, smooth muscle and connective tissues. Two out of 11 (18%) primary tumors (one of which being an adenocarcinoma) expressed low levels of CST6, which might be due to contamination of the tumor material by adjacent normal tissue. Cervical cancer cell lines such as HeLa (D98/AH-2), C41, SiHa, Caski, HT3 and C33A all lack expression of CST6. Treatment of tumor cells by 5-Aza and/or TSA results in 're-expression' of CST6 at levels similar to those seen in normal tissues. Similar to the situation in prostate cancer cells, some cell lines (SiHa and HT3) respond only to TSA treatment. Caski, C33A and C41 cells exhibit both unmethylated and hypermethylated CST6 promoters whereas HeLa cells has homogenously hypermethylated CST6 promoters. Overexpression of CST6 in HeLa and SiHa cells leads in both cases to a reduction in the number and size of colonies forming in soft agar and in cell proliferation. Another consequence of the forced expression of CST6 in HeLa cells is a reduction in intracellular levels of the target protease, cathepsin L, possibly explaining the reduced growth of the CST6 overexpressing cells. Transfection of T98G, LN-229 and U-87MG cells with a mammalian CST6 expression vector resulted in a modest (20-25%) suppression of T98G and LN-229 cell growth when compared to vector controls. Forced expression of CST6 in U-87MG cells had no effect on their capacity to form colonies and proliferate.
Head and neck squamous cell carcinoma (HNSCC)
In conclusion, CST6-mediated suppression of tumor cell growth seems to be most pronounced in cells of epithelial origin, i.e., in cells developing multiple cellto-cell communications and elaborating a basement membrane. Keppler D Atlas Genet Cytogenet Oncol Haematol. 2010; 14(6) 
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Cancer types with increased CST6 expression Squamous cell carcinoma of the skin Note Squamous cell carcinoma (SCC) of the skin versus psoriasis. CST6 is highly expressed in the normal human skin, which might explain why no further increase in expression could be detected in SCC. However, a fiveto six-fold differential expression of CST6 was observed when SCC was compared to psoriatic skin. Differential expression of CST6 was accompanied by a similar differential expression of one of its target proteases, cathepsin L2/V.
Pancreatic cancer
Note CST6 was identified as an upregulated gene in several genome-wide expression studies. One study used microarray analysis to profile gene expression in pancreatic adenocarcinomas (T=10), pancreatic cancer cell lines (C=7), chronic pancreatitis (P=5) and normal pancreas (N=5). According to this study, CST6 levels change 20-, 20-and 24-fold in T/N, T/P and C/N, respectively. In another study using a similar approach (oligo microarray) the T/N ratio was found to be 4.4-fold and upregulation of CST6 was not observed using other platforms such as SAGE or cDNA-based microarrays. Instead, among six genes that were consistently overexpressed across all three platforms was one of the major CST6 targets, cathepsin L2/V. In yet another study using a cDNA microarray, CST6 was found to be overexpressed in 18 microdissected pancreatic ductal adenocarcinomas (PDAC) when compared to normal ductal epithelial cells. Subsequent silencing of CST6 expression in a PDAC cell line (PK-59) reduced colony formation and cell proliferation. Conversely, overexpression of CST6 in a CST6-negative PDAC cell line (KLM-1) promoted tumor growth in nude mice. Likewise, addition of recombinant human CST6 to the growth medium of KLM-1 cells promoted their proliferation in a dosedependent manner. Engineered CST6 variants lacking either N-glycosylation (N137D, figure 3 ) or with an altered protease binding site (deletion of MVG38, figures 3 4) did not have any effect on cell proliferation suggesting that both N-glycosylation and protease specificity are required for oncogenic activity of CST6.
Thyroid cancer
Note Initial immunohistochemical studies found positive staining for CST6 in 80% (8/10) of papillary thyroid carcinomas (PTC) and 73% (11/15) of benign thyroid lesions. Independent studies established a strong correlation between CST6 expression, PTC and BRAF (V600E) mutational status. CST6 expression was also associated with PTC lymph node metastasis.
Ovarian cancer (OvCA)
Note
In order to better define the molecular profiles of the four major histological types of OvCAs (clear cell, mucinous, endometrioid, and serous), a microarray analysis was performed on 113 human specimens. Expression of CST6 was found to be on average 3.8-fold higher in clear cell OvCAs when compared to other histological types. It is interesting to note here that more than one-half of clear cell OvCAs do not exhibit tumor invasion at presentation.
Breakpoints
Note A 300-kb region flanked by the markers D11S4908 and D11S5023 and harboring the CST6 gene has been identified as the minimal tumor deletion on 11q13 in cervical cancer cell lines and primary cervical tumors. This region was reported to contain a high density of DNA repeats rendering it fragile and prone to potential DNA breaks and carcinogenesis. A rare fragile site FRA11A overlaps indeed with this region.
